Sinovac Biotech’s annual production capacity of Covid-19 vaccine can reach 2 billion doses by June, a company spokesman confirmed to Reuters on March 3.
If you are not happy with the results below please do another search
50 search results for:
The United States will have enough Covid-19 vaccine for every American adult by the end of May, President Joe Biden said on March 2 after Merck & Co. agreed to make rival Johnson & Johnson’s inoculation.
Merck entered into multiple agreements to support efforts to expand manufacturing capacity and supply of SARS-CoV-2/Covid-19 medicines and vaccines.
Agilent Technologies, expanding on the company’s precision oncology testing, is acquiring Resolution Bioscience.
Oyster Point’s New Drug Application (NDA) for the dry eye disease therapy OC-01 was accepted for FDA regulatory review on the back of positive Phase III data.
The U.S. National Institutes of Health (NIH) halted a trial of convalescent blood plasma in the treatment of patients with mild-to-moderate Covid-19 symptoms as it was unlikely to benefit this group.
Red Havas announced on March 2 the launch of Red Havas Health, a global micro-network focused on health, in response to increasing demand from clients globally
The U.S. Food and Drug Administration decided to put together an advisory committee meeting of outside experts to review a New Drug Application (NDA) for FibroGen and partner AstraZeneca’s investigational anemia therapy roxadustat.
Novavax Chief Executive Officer Stanley Erck believes the U.S. Food and Drug Administration could grant Emergency Use Authorization (EUA) for the company’s Covid-19 vaccine by May.
Merck & Co. will help make rival Johnson & Johnson’s Covid-19 vaccine in order to boost the slower-than-promised production of the one-dose shot, U.S. President Joe Biden said on March 2.